Piramal Enterprises has concluded the acquisition of a portfolio of drugs for spasticity and pain management from Mallinckrodt LLC.
In January, the company had announced the acquisition for a cash consideration of USD 171 million and up to an additional USD 32 million payable depending on financial performance of the acquired over the next three years.
The company has said in a BSE filing that “Piramal Enterprises announced that its wholly-owned Critical Care subsidiary in the UK has completed its acquisition of a portfolio of drugs for spasticity and pain management from Mallinckrodt LLC.”
